- Home
- CSTL
as of 12-29-2025 3:40pm EST
$39.29
$0.11
-0.27%
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FRIENDSWOOD |
| Market Cap: | 661.7M | IPO Year: | 2019 |
| Target Price: | $42.83 | AVG Volume (30 days): | 364.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.59 - $42.17 | Next Earning Date: | 11-03-2025 |
| Revenue: | $343,530,000 | Revenue Growth: | 10.15% |
| Revenue Growth (this year): | 1.69% | Revenue Growth (next year): | -0.90% |
AI-Powered CSTL Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 69.93%
69.93%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Castle Biosciences Inc. (CSTL)
MAETZOLD DEREK J
Sell
Pres. & Chief Exec. Officer
CSTL Dec 22, 2025
Avg Cost/Share
$40.35
Shares
830
Total Value
$33,490.50
Owned After
33,530
SEC Form 4
MAETZOLD DEREK J
Sell
Pres. & Chief Exec. Officer
CSTL Dec 16, 2025
Avg Cost/Share
$38.55
Shares
12,821
Total Value
$494,300.83
Owned After
33,530
SEC Form 4
MAETZOLD DEREK J
Sell
Pres. & Chief Exec. Officer
CSTL Dec 15, 2025
Avg Cost/Share
$39.03
Shares
19,525
Total Value
$757,098.86
Owned After
33,530
Juvenal Tobin W
Sell
Chief Commercial Officer
CSTL Dec 11, 2025
Avg Cost/Share
$37.48
Shares
13,200
Total Value
$494,736.00
Owned After
86,825
SEC Form 4
Stokes Frank
Sell
Chief Financial Officer
CSTL Dec 11, 2025
Avg Cost/Share
$37.45
Shares
4,496
Total Value
$168,375.20
Owned After
50,326
SEC Form 4
MAETZOLD DEREK J
Sell
Pres. & Chief Exec. Officer
CSTL Dec 4, 2025
Avg Cost/Share
$40.03
Shares
1,339
Total Value
$53,600.17
Owned After
33,530
SEC Form 4
MAETZOLD DEREK J
Sell
Pres. & Chief Exec. Officer
CSTL Dec 2, 2025
Avg Cost/Share
$39.23
Shares
2,678
Total Value
$105,057.94
Owned After
33,530
SEC Form 4
MAETZOLD DEREK J
Sell
Pres. & Chief Exec. Officer
CSTL Nov 26, 2025
Avg Cost/Share
$40.09
Shares
4,258
Total Value
$170,703.22
Owned After
33,530
SEC Form 4
MAETZOLD DEREK J
Sell
Pres. & Chief Exec. Officer
CSTL Nov 25, 2025
Avg Cost/Share
$40.05
Shares
5,115
Total Value
$204,850.64
Owned After
33,530
SEC Form 4
Juvenal Tobin W
Sell
Chief Commercial Officer
CSTL Nov 20, 2025
Avg Cost/Share
$35.58
Shares
4,693
Total Value
$166,976.94
Owned After
86,825
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 22, 2025 | Sell | $40.35 | 830 | $33,490.50 | 33,530 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 16, 2025 | Sell | $38.55 | 12,821 | $494,300.83 | 33,530 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 15, 2025 | Sell | $39.03 | 19,525 | $757,098.86 | 33,530 | |
| Juvenal Tobin W | CSTL | Chief Commercial Officer | Dec 11, 2025 | Sell | $37.48 | 13,200 | $494,736.00 | 86,825 | |
| Stokes Frank | CSTL | Chief Financial Officer | Dec 11, 2025 | Sell | $37.45 | 4,496 | $168,375.20 | 50,326 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 4, 2025 | Sell | $40.03 | 1,339 | $53,600.17 | 33,530 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 2, 2025 | Sell | $39.23 | 2,678 | $105,057.94 | 33,530 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Nov 26, 2025 | Sell | $40.09 | 4,258 | $170,703.22 | 33,530 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Nov 25, 2025 | Sell | $40.05 | 5,115 | $204,850.64 | 33,530 | |
| Juvenal Tobin W | CSTL | Chief Commercial Officer | Nov 20, 2025 | Sell | $35.58 | 4,693 | $166,976.94 | 86,825 |
Latest Castle Biosciences Inc. News
CSTL Breaking Stock News: Dive into CSTL Ticker-Specific Updates for Smart Investing
Zacks
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label
➖
AI Sentiment
Neutral
5/10
Zacks
What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'
📈
AI Sentiment
Highly Positive
9/10
Zacks
GILD Exercises Option to License Assembly Bio's Herpes Programs
📈
AI Sentiment
Highly Positive
8/10
Zacks
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)
📈
AI Sentiment
Highly Positive
10/10
Compare CSTL vs Leading Stocks
See how CSTL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CSTL Castle Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.